Compare LMND & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | BLCO |
|---|---|---|
| Founded | 2015 | 1853 |
| Country | United States | Canada |
| Employees | 1282 | N/A |
| Industry | Property-Casualty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.4B |
| IPO Year | N/A | 2022 |
| Metric | LMND | BLCO |
|---|---|---|
| Price | $67.48 | $15.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $70.86 | $18.45 |
| AVG Volume (30 Days) | ★ 1.4M | 340.4K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $65.20 | $8.65 |
| Revenue Next Year | $33.31 | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $35.70 | $13.09 |
| 52 Week High | $99.90 | $18.92 |
| Indicator | LMND | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 47.04 |
| Support Level | $50.45 | $15.36 |
| Resistance Level | $72.31 | $16.54 |
| Average True Range (ATR) | 4.28 | 0.49 |
| MACD | -0.69 | -0.06 |
| Stochastic Oscillator | 29.24 | 6.21 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.